Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polymerized type I collagen
- Development stage
- Unknown
- Lead developer
- Aspid
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Subcutaneous, Intraarticular, Intralesional, Topical
01
Overview
Polymerized type I collagen (also known as collagen-polyvinylpyrrolidone or collagen-PVP, marketed under the brand name Fibroquel) is a tissue regenerator and immunomodulator developed by Aspid. It is a gamma-irradiated covalent conjugate of pepsinized porcine type I collagen and polyvinylpyrrolidone (PVP) in a citrate buffer solution. Polymerized type I collagen acts as an agonist of leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1), which downregulates STAT-1 phosphorylation and inhibits the expression of pro-inflammatory cytokines (such as IL-1β, TNF-α, IL-8, and IL-17) and cell adhesion molecules. It is approved in Mexico for the treatment of osteoarthritis, wound healing, and abnormal scarring (such as keloids and hypertrophic scars), and has been investigated in Phase III clinical trials for the treatment of rheumatoid arthritis and moderate-to-severe COVID-19.
- Brand names
- Fibroquel
- Other names
- collagen-PVPcollagen-polyvinylpyrrolidonepolymerized-type I collagen
02
Targets
LAIR1 (Leukocyte-associated immunoglobulin-like receptor 1)STAT1 (Signal transducer and activator of transcription protein 1)
Beyond the preview
Go deeper on polymerized type I collagen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polymerized type I collagen.